Article ID Journal Published Year Pages File Type
3943249 Gynecologic Oncology 2009 7 Pages PDF
Abstract
FDR gemcitabine + carboplatin on a 21-day schedule was active and produced no unusual safety signals in patients with Pt-S OC.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Obstetrics, Gynecology and Women's Health
Preview
Fixed-dose rate gemcitabine plus carboplatin in relapsed, platinum-sensitive ovarian cancer patients: Results of a three-arm Phase I study
Authors
, , , , , , , , , ,